The Upstate Carolina Community Clinical Oncology Program (UC-CCOP) has achieved a national reputation for excellence in community cancer care through its 28-year participation in programs of the National Cancer Institute. The UC-CCOP is one of 27 CCOPs that have been continuously funded since 1983. The UC-CCOP seeks to meet the community's need for novel and relevant studies of promising therapeutic and treatment modalities and cancer control and prevention research. The ongoing mission of the UC-CCOP is to assure that every person in the region served is provided an opportunity for participation in a national cancer prevention and/or treatment clinical trial. UC-CCOP strives to provide education about cancer and all NCI clinical trials programs. This grant application encompasses and defines clear objectives of an ever-expanding vision for the UC-CCOP. Goals for this grant cycle: ?Increase patient accrual to cancer treatment, prevention and control clinicl trials sponsored by the NCI and CCOP research bases. ?Increase the number of clinical trial participants from underrepresented populations through continued collaboration with the NCI and proposed strategic initiatives. ?Increase the portfolio of biospecimen/translational clinical trials in collaboration and partnership with participating research bases and the NCI. ?Expand availability of survivorship clinical trials. ?Maintain high-quality data management. ?Improve early phase trial participation through infrastructure and process development. Key strategies to achieving the above goals include (1) expanding the "multidisciplinary approach" to foster the UC-CCOP and Gibbs Cancer Center patient navigator program in order to determine the patient navigator's potential role in and beneficial effects on clinical trial accrual and successful completion of clinical trials, (2) partnering with the NCI to be a pilot site to grow translational research in the community, and (3) utilizing our Minority and Outreach Navigators to strengthen and further develop partnerships with community organizations.
The UC-CCOP continues to provide the community access to the most up-to-date clinical trials available through the NCI. This partnership allows us the opportunity to expand clinical trial accrual in a community-based setting, in turn providing state-of-the-art treatment regardless of race, gender, ethnicity or age.
|Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32|
|Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9|
|Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33|
|Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51|
|Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900|
Showing the most recent 10 out of 166 publications